Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost

Safety and IOP Lowering Efficacy of Low Dose Travoprost Ophthalmic Solutions Dosed BID Compared to TRAVATAN® in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00637130

Enrollment

138

Registered

2008-03-17

Start date

2007-10-31

Completion date

Unknown

Last updated

2012-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle Glaucoma, Ocular Hypertension

Brief summary

The purpose of this study is to compare the safety and IOP-lowering efficacy of various low dose travoprost formulations in patients with open-angle glaucoma or ocular hypertension.

Interventions

DRUGTravoprost ophthalmic solution, 0.0008%

DRUGTravoprost ophthalmic solution, 0.001%

DRUGTravoprost ophthalmic solution, 0.0012%

DRUGTRAVATAN

OTHERVehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients 18 years of age or older, either sex or race with open-angle glaucoma or confirmed ocular hypertension * Other protocol-defined inclusion criteria may apply

Exclusion criteria

* Age related * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean Intraocular Pressure	Up to 2 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026